4B5 scFv (Viventia)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name4B5 scFv (Viventia)
Drug Alias Name4B5 scFv antibody (Novopharm)anti-GD2 antibody (Viventia)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionDisialoganglioside GD2 inhibitors
TargetsDisialoganglioside GD2
Therapy Area/IndicationsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At Birmingham
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViventia Bio Inc
Active IndicationsN/A
Inactive IndicationsMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A